Says expects surgical to improve over time. Says significantly turned around Diabetes business. Says plans to execute IPO of up to 20% of Diabetes business. Says plans to execute spinoff to exchange Diabetes shares for Medtronic (MDT) shares from willing shareholders. Says expecting gross margins to improve following the transaction. Says does not expect any change to dividend policy. Says has visibility to mitigate large portion of tariffs. Says in FY27 expects to return to high-single-digit EPS growth. Comments and guidance taken from Q4 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- MDT Earnings: Medtronic Stock Slips Despite Earnings Beat
- Medtronic Announces Leadership Change in Cardiovascular Portfolio
- Medtronic to separate Diabetes business into new standalone company
- Options Volatility and Implied Earnings Moves Today, May 21, 2025
- Medtronic sees FY26 EPS $5.50-$5.60, consensus $5.83